ALK and anaplastic large cell lymphoma: Therefore, understanding the cellular and molecular mechanisms leading to the development of NPM-ALK(+) ALCL is mandatory to discover potential biomarkers for early detection and consequently novel therapeutic targets to improve the clinical outcome of patients with ALK(+) diseases.